Teva Pharmaceutical Industries Ltd (TEVA): Net Income
$1.41B
Year ended 2025-12-31
$706.00M
Trailing 12 months to 2026-06-30
-1.2%
10-year compound annual growth
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.41B | n/m | 2026-02-03, From 2025-01-01 |
| 2024-12-31 | -$1.64B | n/m | 2026-02-03, From 2024-01-01 |
| 2023-12-31 | -$559.00M | n/m | 2026-02-03, From 2023-01-01 |
| 2022-12-31 | -$2.45B | n/m | 2025-02-05, From 2022-01-01 |
| 2021-12-31 | $417.00M | n/m | 2024-02-12, From 2021-01-01 |
| 2020-12-31 | -$3.99B | n/m | 2023-02-10, From 2020-01-01 |
| 2019-12-31 | -$999.00M | n/m | 2022-02-09, From 2019-01-01 |
| 2018-12-31 | -$2.15B | n/m | 2021-02-10, From 2018-01-01 |
| 2017-12-31 | -$16.27B | n/m | 2020-02-21, From 2017-01-01 |
| 2016-12-31 | $329.00M | -79.3% | 2019-02-19, From 2016-01-07 |
| 2015-12-31 | $1.59B | -48.0% | 2018-02-12, From 2015-01-01 |
| 2014-12-31 | $3.06B | +140.7% | 2017-02-15, From 2014-01-01 |
| 2013-12-31 | $1.27B | -35.4% | 2016-02-11, From 2013-01-01 |
| 2012-12-31 | $1.96B | -28.9% | 2015-02-09, From 2012-01-01 |
| 2011-12-31 | $2.76B | -17.2% | 2014-02-10, From 2011-01-01 |
| 2010-12-31 | $3.33B | +66.6% | 2013-02-12, From 2010-01-01 |
| 2009-12-31 | $2.00B | +228.4% | 2012-02-17, From 2009-01-01 |
| 2008-12-31 | $609.00M | -68.2% | 2011-02-15, From 2008-01-01 |
| 2007-12-31 | $1.91B | n/a | 2010-02-22, From 2007-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $1.41B | n/m |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $4.50B | +2.1% |
| Viatris Inc (VTRS) | 2025-12-31 | -$3.51B | n/m |
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $3.95B | n/m |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $120.00M | n/m |
| Zoetis Inc. (ZTS) | 2025-12-31 | $2.67B | +7.5% |
| Abbott Laboratories (ABT) | 2025-12-31 | $6.52B | -51.3% |
| Organon & Co. (OGN) | 2025-12-31 | $187.00M | -78.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $7.05B | n/m |
Compare TEVA, REGN, VTRS, VRTX side by side · Screen every company in Pharmaceutical Preparations ↗